Study summary
Low-dose aspirin halved recurrence in cancers with PI3K-pathway mutations
7.7%recurrence at 3 years, vs 14.1% with placebo
What was tested
Aspirin 160 mg daily or placebo for 3 years after treatment for stage I to III colorectal cancer with PIK3CA or other PI3K-pathway mutations (about 1 in 3 tumors).
What they found
- 3-year recurrence was 7.7% vs 14.1% in people with PIK3CA hotspot mutations.
- Severe side effects were 16.8% vs 11.6%.
What it means
Tumor testing for PI3K-pathway mutations may guide aspirin use; a separate trial after liver metastases found no benefit.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.